vs
Apellis Pharmaceuticals, Inc.（APLS）与Beacon Financial Corp（BBT）财务数据对比。点击上方公司名可切换其他公司
Beacon Financial Corp的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$216.7M vs $199.9M），Beacon Financial Corp净利率更高（24.6% vs -29.5%，领先54.1%），过去两年Beacon Financial Corp的营收复合增速更高（41.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
倍肯屋面供应公司是北美知名的建筑材料供应商，主营住宅及非住宅类屋面产品及相关建材。截至2023年12月31日，公司在美国全部50个州和加拿大6个省共设有533个网点，员工超8000人，除屋面材料外，各地分部还销售门窗、壁板、防水材料等各类户外建筑产品。
APLS vs BBT — 直观对比
营收规模更大
BBT
是对方的1.1倍
$199.9M
净利率更高
BBT
高出54.1%
-29.5%
两年增速更快
BBT
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $216.7M |
| 净利润 | $-59.0M | $53.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 24.6% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | 179.4% |
| 每股收益（稀释后） | $-0.40 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSBBT
| Q1 26 | — | $216.7M | ||
| Q4 25 | $199.9M | $225.7M | ||
| Q3 25 | $458.6M | $141.2M | ||
| Q2 25 | $178.5M | $113.7M | ||
| Q1 25 | $166.8M | $110.4M | ||
| Q4 24 | $212.5M | $110.2M | ||
| Q3 24 | $196.8M | $125.6M | ||
| Q2 24 | $199.7M | $108.7M |
净利润APLSBBT
| Q1 26 | — | $53.4M | ||
| Q4 25 | $-59.0M | $53.4M | ||
| Q3 25 | $215.7M | $-4.2M | ||
| Q2 25 | $-42.2M | $22.0M | ||
| Q1 25 | $-92.2M | $19.1M | ||
| Q4 24 | $-36.4M | $17.5M | ||
| Q3 24 | $-57.4M | $20.1M | ||
| Q2 24 | $-37.7M | $16.4M |
营业利润率APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -5.9% | ||
| Q2 25 | -18.6% | 26.0% | ||
| Q1 25 | -50.0% | 23.1% | ||
| Q4 24 | -12.3% | 21.6% | ||
| Q3 24 | -24.0% | 21.3% | ||
| Q2 24 | -14.7% | 19.9% |
净利率APLSBBT
| Q1 26 | — | 24.6% | ||
| Q4 25 | -29.5% | 23.6% | ||
| Q3 25 | 47.0% | -3.0% | ||
| Q2 25 | -23.6% | 19.4% | ||
| Q1 25 | -55.3% | 17.3% | ||
| Q4 24 | -17.1% | 15.9% | ||
| Q3 24 | -29.2% | 16.0% | ||
| Q2 24 | -18.9% | 15.1% |
每股收益（稀释后）APLSBBT
| Q1 26 | — | $0.55 | ||
| Q4 25 | $-0.40 | $0.64 | ||
| Q3 25 | $1.67 | $-0.05 | ||
| Q2 25 | $-0.33 | $0.25 | ||
| Q1 25 | $-0.74 | $0.21 | ||
| Q4 24 | $-0.30 | $0.20 | ||
| Q3 24 | $-0.46 | $0.23 | ||
| Q2 24 | $-0.30 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $927.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.5B |
| 总资产 | $1.1B | $22.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSBBT
| Q1 26 | — | $927.3M | ||
| Q4 25 | $466.2M | $1.8B | ||
| Q3 25 | $479.2M | $1.2B | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $543.7M | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
总债务APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $225.6M | ||
| Q1 25 | — | $284.6M | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $353.6M | ||
| Q2 24 | — | $278.6M |
股东权益APLSBBT
| Q1 26 | — | $2.5B | ||
| Q4 25 | $370.1M | $2.5B | ||
| Q3 25 | $401.2M | $2.4B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.2B | ||
| Q3 24 | $237.1M | $1.2B | ||
| Q2 24 | $264.3M | $1.2B |
总资产APLSBBT
| Q1 26 | — | $22.2B | ||
| Q4 25 | $1.1B | $23.2B | ||
| Q3 25 | $1.1B | $22.8B | ||
| Q2 25 | $821.4M | $12.0B | ||
| Q1 25 | $807.3M | $12.0B | ||
| Q4 24 | $885.1M | $11.9B | ||
| Q3 24 | $901.9M | $11.6B | ||
| Q2 24 | $904.5M | $12.2B |
负债/权益比APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $-4.8M | ||
| Q2 25 | $4.4M | $38.5M | ||
| Q1 25 | $-53.4M | $23.3M | ||
| Q4 24 | $19.4M | $105.0M | ||
| Q3 24 | $34.1M | $19.9M | ||
| Q2 24 | $-8.3M | $34.8M |
自由现金流APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $-5.9M | ||
| Q2 25 | $4.4M | $36.3M | ||
| Q1 25 | $-53.4M | $19.9M | ||
| Q4 24 | $19.3M | $100.0M | ||
| Q3 24 | — | $17.2M | ||
| Q2 24 | $-8.4M | $34.4M |
自由现金流率APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | -4.2% | ||
| Q2 25 | 2.5% | 31.9% | ||
| Q1 25 | -32.0% | 18.0% | ||
| Q4 24 | 9.1% | 90.7% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | -4.2% | 31.7% |
资本支出强度APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.0% | 2.1% | ||
| Q2 24 | 0.0% | 0.3% |
现金转化率APLSBBT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 1.75× | ||
| Q1 25 | — | 1.22× | ||
| Q4 24 | — | 5.99× | ||
| Q3 24 | — | 0.99× | ||
| Q2 24 | — | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BBT
| Net Interest Income | $190.8M | 88% |
| Noninterest Income | $25.9M | 12% |
